KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 50 filers reported holding KEROS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,925,104 | -29.5% | 3,604,928 | -11.2% | 0.01% | -28.6% |
| Q2 2023 | $163,092,266 | -52.9% | 4,059,041 | -49.9% | 0.01% | -12.5% |
| Q1 2023 | $346,029,954 | +95.9% | 8,103,746 | +120.3% | 0.02% | -11.1% |
| Q4 2022 | $176,669,854 | +21.6% | 3,679,089 | -4.8% | 0.02% | +20.0% |
| Q3 2022 | $145,346,000 | +46.1% | 3,863,526 | +7.3% | 0.02% | +50.0% |
| Q2 2022 | $99,465,000 | -39.2% | 3,599,895 | +19.7% | 0.01% | -23.1% |
| Q1 2022 | $163,571,000 | -20.2% | 3,007,936 | -14.2% | 0.01% | -13.3% |
| Q4 2021 | $205,066,000 | +48.1% | 3,504,798 | +0.1% | 0.02% | +36.4% |
| Q3 2021 | $138,487,000 | -6.7% | 3,500,679 | +0.2% | 0.01% | -8.3% |
| Q2 2021 | $148,413,000 | -17.7% | 3,494,539 | +19.3% | 0.01% | -20.0% |
| Q1 2021 | $180,226,000 | -3.4% | 2,928,117 | +10.7% | 0.02% | -11.8% |
| Q4 2020 | $186,551,000 | +170.4% | 2,644,620 | +47.9% | 0.02% | +142.9% |
| Q3 2020 | $68,984,000 | +35.3% | 1,788,545 | +31.5% | 0.01% | +16.7% |
| Q2 2020 | $51,001,000 | – | 1,359,672 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |